Victor Moyo

Dr. Moyo is an Oncologist/Hematologist with substantial experience in the development of novel therapeutic and companion diagnostic approaches to cancer.

Prior to joining L.E.A.F. Pharmaceuticals, he served as Vice President of Clinical

Investigations at Merrimack Pharmaceuticals, providing clinical support for oncology

programs including Pre-IND programs, First-in-Human, Phase 1 multi-arm safety and tolerability, and Phase 2 proof of concept studies involving multiple programs.

Dr. Moyo has also supported registration studies with the USFDA and other regulatory agencies. Most recently, he was involved in the development and approval of ONIVYDE®, for the treatment of advanced pancreatic cancer. Prior to Merrimack Pharmaceuticals, Dr. Moyo’s experience includes service as Medical Director for Centocor-Ortho Biotech (Johnson and Johnson) and service as Assistant Professor in the Department of Medicine, Division of Hematology/ Oncology, University of Connecticut Medical Center, in Farmington, CT.

Dr. Moyo holds an MBChB (MD) degree from the School of Medicine, University of

Zimbabwe, and did internships at Mpilo Central Hospital, Bulawayo Zimbabwe and The George Washington University Medical Center, Washington, D.C. where he also completed his Residency in Internal Medicine. He also completed a fellowship in Hematology and Oncology at Johns Hopkins Hospital in Baltimore, MD.

Dr. Moyo also has experience conducting clinical research in central and southern

Africa and has published on various other topics including iron overload disorders and malaria. He is also a co-inventor of several patents involving the treatment of several cancers.